Clinical Development Services

Once a compound successfully clears preclinical studies, it enters clinical drug development, a highly structured series of phases involving human participants:

Phase I: First-in-Human Safety and Dosing

This initial phase of clinical drug development involves a small group of healthy volunteers or patients. The primary goal is to assess the drug’s safety, determine a safe dosage range, and study how the drug is absorbed, metabolized, and excreted by the body (pharmacokinetics).

Phase II: Efficacy and Dose Optimization

In Phase II, the drug is administered to a larger group of patients who have the disease or condition the drug is intended to treat. The focus shifts to evaluating the drug’s effectiveness, further assessing safety, and determining the optimal dosage and treatment regimen.

Phase III: Pivotal Trials for Efficacy and Safety Confirmation

Phase III trials are large-scale, often multi-center studies involving hundreds to thousands of patients. The primary objective is to confirm the drug’s efficacy, monitor adverse reactions, and compare it to existing treatments or a placebo. Successful completion of Phase III trials is typically required for regulatory approval. These large-scale studies represent the most resource-intensive phase of Clinical Development, confirming both efficacy and safety.

Phase IV: Post-Marketing Surveillance

Even after a drug is approved and marketed, clinical drug development continues with Phase IV studies. These involve ongoing surveillance to monitor the drug’s long-term safety and effectiveness in diverse populations, and to identify any rare or long-term side effects.